At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 395 enrolled
Drug / intervention
GSK3511294 (Depemokimab) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
In Brief
A Phase 3 clinical trial evaluating GSK3511294 (Depemokimab) and Placebo for Asthma. Completed, enrolled 395 participants across 123 sites in 12 countries.
Detailed Summary
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, China, Czechia, France, Germany, Ireland, Italy, Poland, Russia, Spain, United Kingdom, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionNov 2023
TodayJul 2026
First PostedJan 22, 2021
Enrollment StartMar 17, 2021
Primary CompletionNov 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.4 years ago
Interventions
GSK3511294 (Depemokimab)biological
GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
Placebodrug
Matching placebo will be administered as a normal saline using a pre-filled syringe.